Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Across these trials, 1.35% (279 of 20,598) of participants who received a GLP-1 RA had ≥1 episode of AFib reported as a serious adverse event, compared with 1.37% (282 of 20,608) of those who ...

The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers (OACs ...

GLP-1 RAs can reduce liver fat, fibrosis progression, and resolve MASH, offering potential benefits for liver health. MASH significantly increases healthcare costs due to comorbidities like ...

There was a 132.6 percent increase in patients prescribed GLP-1 RAs between the last six months of 2022 and the last six months of 2023 (1.89 versus 4.41 patients per 1,000 patients).

Originally developed for type 2 diabetes, GLP-1 RAs have gained significant traction globally for obesity treatment. With 32% of Australians classified as obese in 2022 and the cost of obesity ...